Evidence Grade A — Regulatory approved. 24 published studies. 10 registered clinical trials.
Medically reviewed by a licensed medical professional
Loading...
Motixafortide (sold as Aphexda) is used to prepare multiple myeloma patients for stem cell transplant by flushing blood-forming stem cells out of the bone marrow and into the bloodstream where they can be collected. In the pivotal trial, a single injection dramatically increased the number of stem cells collected, with over two-thirds of patients meeting the target goal in just one or two collection sessions compared to fewer than 10% without it.
Motixafortide is also known by these brand and alternate names:
24 published studies: 17 human, 1 animal, 0 in-vitro, 13 reviews
Motixafortide is marketed as Aphexda (approved September 2023) for mobilisation of haematopoietic stem cells for collection and subsequent autologous transplantation in multiple myeloma patients, used in combination with G-CSF.
In the GENESIS trial, 92.5% of patients treated with motixafortide plus G-CSF achieved the target stem cell collection in two or fewer apheresis sessions, compared to 26.2% with G-CSF plus placebo. Over two-thirds achieved the target in a single session. This is a significant practical improvement — each apheresis session takes several hours and is physically demanding for patients who are already unwell. Motixafortide competes with plerixafor (Mozobil), an earlier CXCR4 antagonist, with substantially higher single-session success rates.
Blood stem cells are held in the bone marrow by a molecular tethering system — the CXCR4 receptor on stem cells binds to a protein called SDF-1 (CXCL12) produced by bone marrow stromal cells, keeping them anchored in place. Motixafortide blocks CXCR4, cutting this tether. Combined with G-CSF (another mobilising agent), this releases a large wave of stem cells into the bloodstream. The more stem cells collected per session, the fewer apheresis procedures the patient needs — and motixafortide dramatically increases yield per session.
The GENESIS trial demonstrated clear superiority: 92.5% of patients receiving motixafortide plus G-CSF achieved the stem cell collection target in up to two apheresis sessions, compared to 26.2% with G-CSF plus placebo. The median stem cell yield in a single session was nearly five times higher with motixafortide. For patients, this translates to fewer collection procedures — each of which takes several hours and is physically taxing — and more reliable collection overall. Motixafortide competes with plerixafor (Mozobil), an older CXCR4 antagonist, and appears to offer substantially higher single-session success rates. The main side effects are injection-site reactions, itching, flushing, and back pain. An earlier study of motixafortide in pancreatic cancer (the COMBAT trial) did not succeed, and the drug is currently approved only for stem cell mobilisation. Research is ongoing for potential use in gene therapy applications for sickle cell disease.
PeptideTrace tracks 10 registered clinical trials for Motixafortide sourced from ClinicalTrials.gov.
Motixafortide for MRD Sensitization in AML
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
Gene Editing For Sickle Cell Disease
SCD Stem Cell Mobilization and Apheresis Using Motixafortide
FDA ORIG 1
FDA SUPPL 9
Motixafortide (BL-8040) is a cyclic 14-amino-acid synthetic peptide, MW ~1,829 Da. High-affinity CXCR4 antagonist incorporating non-natural amino acids (naphthalanine, citrulline) and disulfide bridge. Ki ~1 nM for CXCR4. SC 1.25 mg/kg. Pharmacodynamic effect (CD34+ mobilization) persists 24-34 hours enabling single-day collection protocols.
Binds CXCR4, antagonizing SDF-1/CXCL12. Disrupts HSPC bone marrow retention (VCAM-1/VLA-4, SCF/c-Kit adhesive interactions), mobilizing CD34+ cells to peripheral blood for apheresis collection. Also induces AML blast apoptosis by disrupting leukemia-stroma microenvironment. Prolonged receptor occupancy relative to plerixafor.
Marketed as Aphexda. Approved September 9, 2023. GENESIS (Phase III; N=122): 92.5% vs. 26.2% achieved >=6x10^6 CD34+ cells/kg in <=2 sessions (P<0.0001). 67.2% in single session vs. 9.5%. Median collected 17.0 vs. 5.3x10^6/kg. Indication: HSPC mobilization for autologous transplant in MM, with G-CSF.
Vancomycin is marketed as Vancocin and Firvanq (approved 1958, with oral solution Firvanq approved 2018). It is the standard treatment for serious MRSA infections (bloodstream infections, endocarditis, pneumonia, bone infections) and is first-line for severe C. difficile colitis. Vancomycin requires therapeutic drug monitoring — blood levels must be checked regularly to ensure the dose is effective without causing kidney damage or hearing loss. The rise of vancomycin-resistant enterococci (VRE) and occasional vancomycin-intermediate S. aureus (VISA) strains represent ongoing challenges. Despite being nearly 70 years old, vancomycin remains irreplaceable for many serious infections, though newer alternatives like daptomycin and the lipoglycopeptides offer advantages in specific settings.
Zilucoplan is marketed as Zilbrysq (approved October 2023) for anti-acetylcholine receptor antibody-positive generalised myasthenia gravis in adults. Administered as a daily subcutaneous self-injection. In the RAISE trial, zilucoplan showed statistically significant improvements in both activities of daily living and quantitative muscle strength scores compared to placebo, with improvements evident from week one. Its key differentiator from existing complement inhibitors (eculizumab, ravulizumab) is the self-injectable format — those alternatives require hospital-based intravenous infusions. As with all complement inhibitors, patients require meningococcal vaccination before starting treatment due to increased susceptibility to meningococcal infection.
Daptomycin is marketed as Cubicin (approved September 2003). It is indicated for complicated skin and soft tissue infections and S. aureus bloodstream infections including right-sided endocarditis. Administered as a once-daily intravenous infusion. A key limitation is that daptomycin cannot be used for pneumonia — lung surfactant inactivates the drug. In the bacteraemia trial, daptomycin was non-inferior to vancomycin with significantly lower rates of kidney problems (11% versus 26%). Creatine kinase (CK) levels must be monitored during treatment, as daptomycin can cause muscle toxicity. Generics became available after patent expiry, significantly reducing cost.
Evidence Reviews
Regulatory Status
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
